PHASE 1B STUDY OF THE SRC INHIBITOR DASATINIB WITH FOLFOX AND CETUXIMAB IN REFRACTORY METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Kopetz, S. [1 ]
Wolff, R. [1 ]
Eng, C. [1 ]
Overman, M. [1 ]
Henry, L. [1 ]
Coulson, R. [1 ]
Garrett, C. [1 ]
Abbruzzese, J. [1 ]
Gallick, G. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [41] Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
    Tintelnot, Joseph
    Ristow, Inka
    Sauer, Markus
    Simnica, Donjete
    Schultheiss, Christoph
    Scholz, Rebekka
    Goekkurt, Eray
    von Wenserski, Lisa
    Willscher, Edith
    Paschold, Lisa
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas J.
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Hinke, Axel
    Bauer, Marcus
    Massa, Chiara
    Seliger, Barbara
    Wickenhauser, Claudia
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Binder, Mascha
    Stein, Alexander
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients
    Gandhi, Anita K.
    Shi, Tao
    Li, Mingyu
    Jungnelius, Ulf
    Romano, Alfredo
    Tabernero, Josep
    Siena, Salvatore
    Schafer, Peter H.
    Chopra, Rajesh
    PLOS ONE, 2013, 8 (11):
  • [43] RANDOMIZED PHASE II STUDY EVALUATING UFOX PLUS CETUXIMAB VERSUS FOLFOX4 PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER: FUTURE
    Douillard, Jean-Yves
    Zemelka, Tomasz
    Fountzilas, Georgios
    Barone, Carlo
    Schlichting, Michael
    Eggleton, S. Peter
    Srimuninnimit, Vichien
    ANNALS OF ONCOLOGY, 2012, 23 : 11 - 12
  • [44] A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
    Noonan, Anne M.
    Lustberg, Maryam B.
    Schnell, Patrick
    Hays, John L.
    Jin, Ning
    Abushahin, Laith, I
    Malalur, Pannaga G.
    Roychowdhury, Sameek
    Elkhatib, Rifat T.
    Chen, Huizi
    Al Mutar, Salwan
    Sparreboom, Alex
    Hu, Shuiying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Multicenter Phase II Study of FOLFOX for Metastatic Colorectal Cancer (mCRC) in Japan; SWIFT-1 and 2 study
    Nagata, N.
    Kondo, K.
    Kato, T.
    Shibata, Y.
    Okuyama, Y.
    Ikenaga, M.
    Tanemura, H.
    Oba, K.
    Nakao, Akimasa
    Sakamoto, J.
    Mishima, H.
    HEPATO-GASTROENTEROLOGY, 2009, 56 (94-95) : 1346 - 1353
  • [46] Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
    Finn, R. S.
    Ahn, D. H.
    Javle, M. M.
    Tan, B. R.
    Weekes, C. D.
    Bendell, J. C.
    Patnaik, A.
    Khan, G. N.
    Laheru, D.
    Chavira, R.
    Christy-Bittel, J.
    Barrett, E.
    Sawyer, M. B.
    Bekaii-Saab, Tanios S.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1037 - 1043
  • [47] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Astrid Lièvre
    Emmanuelle Samalin
    Emmanuel Mitry
    Eric Assenat
    Christine Boyer-Gestin
    Céline Lepère
    Jean-Baptiste Bachet
    Fabienne Portales
    Jean-Nicolas Vaillant
    Marc Ychou
    Philippe Rougier
    BMC Cancer, 9
  • [48] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Lievre, Astrid
    Samalin, Emmanuelle
    Mitry, Emmanuel
    Assenat, Eric
    Boyer-Gestin, Christine
    Lepere, Celine
    Bachet, Jean-Baptiste
    Portales, Fabienne
    Vaillant, Jean-Nicolas
    Ychou, Marc
    Rougier, Philippe
    BMC CANCER, 2009, 9 : 347
  • [49] Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
    R. S. Finn
    D. H. Ahn
    M. M. Javle
    B. R. Tan
    C. D. Weekes
    J. C. Bendell
    A. Patnaik
    G. N. Khan
    D. Laheru
    R. Chavira
    J. Christy-Bittel
    E. Barrett
    M. B. Sawyer
    Tanios S. Bekaii-Saab
    Investigational New Drugs, 2018, 36 : 1037 - 1043
  • [50] A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
    Eng, Cathy
    Lakhani, Nehal J.
    Philip, Philip A.
    Schneider, Charles
    Johnson, Benny
    Kardosh, Adel
    Chao, Mark P.
    Patnaik, Amita
    Shihadeh, Fadi
    Lee, Yeonju
    Song, Kai
    Jin, Denise
    Huo, Yanan
    Howland, Michael
    Fisher, George A.
    Hecht, J. Randolph
    TARGETED ONCOLOGY, 2025,
12345